Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975284 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL11491429 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL968055 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975291 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL8838682 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL9547867 | 1.00 | CA2 (0.32) | CA2MEN1KMT2ACA1 | |
| SCHEMBL4975685 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405856 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL4975682 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A | |
| SCHEMBL11405854 | 0.98 | MEN1 (0.32) | CA2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0624574-B1 | Novel prostaglandin analogue | MIZUSHIMA YUTAKA (JP) | 1999-04-21 | — | — | EP | claimed |
| EP-0624574-A2 | Novel prostaglandin analogue | MIZUSHIMA, Yutaka (JP) | 1994-11-17 | — | — | EP | claimed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| EP-2864308-B1 | (3aR,6aS)-2-Hydroxy-3,3a,6,6a-tetrahydro-2H-cyclopenta[b]furan-5-carbaldehyde intermediates for the preparation of prostaglandins or prostaglandin analogues | UNIV BRISTOL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PATHEON API SERVICES INC. | 2016-08-18 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242954-B2 | Lactol and acetal intermediates for making prostaglandins | UNIVERSITY OF BRISTOL (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158837-A1 | Compound And Method | TOPOKINE THERAPEUTICS, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-0312055-A2 | 6-Fluoroprostaglandins | ASAHI GLASS COMPANY LTD. (JP) | 1989-04-19 | — | — | EP | disclosed |
| EP-0102230-B1 | NOVEL 6-NITROPROSTAGLANDIN DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND USE THEREOF | TEIJIN LIMITED (JP) | 1987-04-29 | — | — | EP | disclosed |
| US-4649156-A | ANTICOAGULANTS, HYPOTENSIVE, VASODILATORS, ANTITUMOR | TEIJIN LIMITED (JP) | 1987-03-10 | — | — | US | disclosed |
| EP-0178139-A2 | Process for producing 2,3-disubstituted -4-substituted cyclopentanones, enantiomorphs, or mixtures thereof | TEIJIN LIMITED (JP) | 1986-04-16 | — | — | EP | disclosed |
| EP-0173754-A1 | 7-THIAPROSTAGLANDIN E 1?'S AND PROCESS FOR THEIR PREPARATION | TEIJIN LIMITED (JP) | 1986-03-12 | — | — | EP | disclosed |
| EP-0051284-B1 | NOVEL THIAPROSTAGLANDIN E1 DERIVATIVES, PROCESS FOR PRODUCTION THEREOF, AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | TEIJIN LIMITED (JP) | 1985-01-09 | — | — | EP | disclosed |
| US-4466980-A | Thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-08-21 | — | — | US | disclosed |
| EP-0102230-A2 | Novel 6-nitroprostaglandin derivatives, process for production thereof, and use thereof | TEIJIN LIMITED (JP) | 1984-03-07 | — | — | EP | disclosed |
| EP-0051284-A1 | Novel thiaprostaglandin E1 derivatives, process for production thereof, and pharmaceuticals containing these compounds | TEIJIN LIMITED (JP) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237056-A1 | NOVEL SYNTHESIS ROUTES FOR PROSTAGLANDINS AND PROSTAGLANDIN INTERMEDIATES USING METATHESIS | PTGES, PTGIS, PTGES2 | CA2 1336/4885MEN1 692/4885KMT2A 4105/4885 |
| US-20150158837-A1 | Compound And Method | CYP4A11, NR1H2, NR1H3 | CA2 3363/4885MEN1 2871/4885KMT2A 3218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.